全文获取类型
收费全文 | 18032篇 |
免费 | 1041篇 |
国内免费 | 98篇 |
专业分类
耳鼻咽喉 | 130篇 |
儿科学 | 326篇 |
妇产科学 | 331篇 |
基础医学 | 2995篇 |
口腔科学 | 384篇 |
临床医学 | 1471篇 |
内科学 | 3257篇 |
皮肤病学 | 711篇 |
神经病学 | 1978篇 |
特种医学 | 1258篇 |
外科学 | 2291篇 |
综合类 | 80篇 |
一般理论 | 6篇 |
预防医学 | 734篇 |
眼科学 | 309篇 |
药学 | 1719篇 |
中国医学 | 23篇 |
肿瘤学 | 1168篇 |
出版年
2023年 | 63篇 |
2022年 | 120篇 |
2021年 | 208篇 |
2020年 | 191篇 |
2019年 | 232篇 |
2018年 | 250篇 |
2017年 | 245篇 |
2016年 | 322篇 |
2015年 | 412篇 |
2014年 | 493篇 |
2013年 | 636篇 |
2012年 | 971篇 |
2011年 | 1122篇 |
2010年 | 691篇 |
2009年 | 699篇 |
2008年 | 1136篇 |
2007年 | 1202篇 |
2006年 | 1161篇 |
2005年 | 1137篇 |
2004年 | 1127篇 |
2003年 | 1173篇 |
2002年 | 1131篇 |
2001年 | 238篇 |
2000年 | 167篇 |
1999年 | 245篇 |
1998年 | 304篇 |
1997年 | 256篇 |
1996年 | 225篇 |
1995年 | 195篇 |
1994年 | 176篇 |
1993年 | 176篇 |
1992年 | 127篇 |
1991年 | 112篇 |
1990年 | 101篇 |
1989年 | 107篇 |
1988年 | 116篇 |
1987年 | 93篇 |
1986年 | 73篇 |
1985年 | 79篇 |
1984年 | 97篇 |
1983年 | 90篇 |
1982年 | 96篇 |
1981年 | 98篇 |
1980年 | 105篇 |
1979年 | 58篇 |
1978年 | 62篇 |
1977年 | 80篇 |
1976年 | 63篇 |
1975年 | 58篇 |
1974年 | 69篇 |
排序方式: 共有10000条查询结果,搜索用时 328 毫秒
991.
Poliomyelitis and Parkinson disease 总被引:2,自引:0,他引:2
992.
Aim of the study: Is it possible to use the Internet as a secure media for transport of telemedicine? Which risks exist for routine use? In this article state of the art methods of security were analysed. Telemedicine in the Internet has severe risks, because patient data and hospital data of a secure Intranet can be manipulated by connecting it to the Web. Conclusions: Establishing of a firewall and the introduction of HPC (Health Professional Card) are minimizing the risk of un-authorized access to the hospital server. HPC allows good safety with digital signature and authentication of host and client of medical data. For secure e-mail PGP (Pretty Good Privacy) is easy to use as a standard protocol. Planning all activities exactly as well as following legal regulations are important requisites for reduction of safety risks in Internet. 相似文献
993.
Froelich JJ El-Sheik M Wagner HJ Achenbach S Scherf C Klose KJ 《Cardiovascular and interventional radiology》2000,23(6):423-430
Purpose: Evaluation of C-arm-supported CT fluoroscopy to facilitate percutaneous abscess drainage procedures.
Methods: Prospectively, 40 percutaneous drainage procedures were performed either with C-arm-supported CT fluoroscopy or with CT fluoroscopy
alone. Hybrid imaging was performed on the CT couch after complementing a CT fluoroscopy scanner with a C-arm fluoroscopy
unit. Procedure times, drainage revisions during follow-up, and postinterventional drainage periods were analyzed.
Results: When compared with exclusive CT fluoroscopic guidance, a median procedure time of 9 ± 3.7 min versus 14.8 ± 7.3 min was required
for C-arm-supported CT fluoroscopy (p < 0.005, t-test). During follow-up, eight drainage catheters had to be revised within the exclusive CT fluoroscopy group, while only
two revisions were necessary within the C-arm-supported CT fluoroscopy group. With C-arm-supported CT fluoroscopy, postinterventional
drainage periods were reduced (median 13 vs 19 days; p < 0.001, t-test).
Conclusion: Compared with exclusive cross-sectional image guidance, C-arm-supported CT fluoroscopy seems to improve placement of abscess
drainage catheters to possibly reduce procedure times, drainage catheter revisions, and postinterventional drainage periods. 相似文献
994.
Interventional uroradiologic procedures performed using gadodiamide as an alternative to iodinated contrast material 总被引:2,自引:0,他引:2
Spinosa DJ Angle JF Hagspiel KD Hartwell GD Jenkins AD Matsumoto AH 《Cardiovascular and interventional radiology》2000,23(1):72-75
Three patients with either a history of severe allergic reactions to iodinated contrast or marked renal insufficiency underwent interventional uroradiologic procedures using full-strength gadodiamide (Gd) as a contrast agent in place of iodinated contrast material. The procedures were percutaneous access for nephrostolithotomy, antegrade pyelography with placement of a nephroureteral stent, and a diagnostic nephrostogram with exchange of a nephroureteral stent. Gd was visualized fluoroscopically and produced satisfactory digital radiographs without allergic reaction or worsening renal function. Gd can be useful in guiding interventional uroradiologic procedures when iodinated contrast material is contraindicated. 相似文献
995.
Michail Plotkin Uwe Gneveckow Klaus Meier-Hauff Holger Amthauer Annelie Feussner Timm Denecke Matthias Gutberlet Andreas Jordan Roland Felix Peter Wust 《International journal of hyperthermia》2006,22(4):319-325
PURPOSE: Thermotherapy using magnetic nanoparticles (nano cancer therapy) is a new concept of local tumour therapy, which is based on controlled heating of intra-tumoural injected magnetic nanoparticles. The aim of this study was to evaluate the usefulness of PET with a recently introduced amino acid tracer O-(2-[18F]fluoroethyl)-]L-tyrosine (FET) for targeting the nanoparticles implantation. MATERIALS AND METHODS: Eleven patients with glioblastoma recurrences underwent MR and FET-PET imaging for planning of the nano cancer therapy. Thereafter, the gross tumour volumes (GTV) were defined, taking into consideration the results of both imaging tools. RESULTS: The MRI-based mean GTV was 24.3 cm3 (range 2.5-59.7) and the PET-based mean GTV 31.9 cm3 (range 5.2-77.9). On the average the MRI identified an additional 8.9 +/- 4.7 cm3 and the FET-PET scan-an additional 16.5 +/- 15.2 cm3 outside of the common GTV (15.4 +/- 11.0 cm3). The mean final GTV accounted to 33.8 cm3 (range, 5.2-77.9). The additional information of FET-PET led to an increase in GTV by 22-286% in eight patients and to a decrease of 23% and 26%, respectively, in two patients. In one patient, the final GTV was defined on the basis of MRI data only. CONCLUSIONS: FET-PET adds important information on the actual tumour volume in recurrent glioblastomas and is highly valuable for defining the target volume for the nano cancer therapy. 相似文献
996.
997.
Sylvia Rabstein Klaus Unfried Ulrich Ranft Thomas Illig Melanie Kolz Hans-Peter Rihs Chinara Mambetova Mariana Vlad Thomas Brüning Beate Pesch 《Cancer epidemiology, biomarkers & prevention》2006,15(1):138-141
As part of a project on environmental disasters in minority populations, this study aimed to evaluate differences in the sequence of N-acetyltransferase 2 (NAT2) as a metabolic susceptibility gene in yet unexplored ethnicities. Eight single nucleotide polymorphisms (SNP) in the NAT2 coding region and a variant in the 3' flanking region were analyzed in 290 unrelated Kyrgyz and 140 unrelated Romanians by SNP-specific PCR analysis. The variants 341C, 481T, and 803G were less and 857A more prevalent in Kyrgyz (P < 0.0001). The variant at site 857 indicates Asian descent. 282C>T and 590G>A showed no significant variation by ethnicity. 364G>A and 411A>T turned out to be monomorphic. Database comparisons of the NAT2 minor allele frequencies support that Romanians belong to Caucasians and Kyrgyz are in between Caucasians and East Asians. The distributions of predicted haplotypes differed significantly between the two ethnicities where the Kyrgyz showed a higher genetic diversity. The haplotype without mutations was more common in Kyrgyz (40.1% in Kyrgyz, 29.3% in Romanians). Accordingly, the imputed slow acetylator phenotype was less prevalent in Kyrgyz (35.2% versus 51.4% in Romanians). We found pronounced ethnic differences in NAT2 genotypes with yet unknown effect on the health risks for environmental or occupational exposures in minority populations. 相似文献
998.
Boris Kubuschok Frank Neumann Rainer Breit Martina Sester Claudia Schormann Claudia Wagner Urban Sester Frank Hartmann Mathias Wagner Klaus Remberger Martin Schilling Michael Pfreundschuh 《Clinical cancer research》2006,12(4):1365-1372
Mutated p21 ras proteins (muRas) are present in approximately 90% of pancreatic adenocarcinomas and express mutants which can function as cancer-specific antigens. To evaluate the frequency and magnitude of the natural T-cell response against muRas in 19 HLA-A2-positive patients with muRas-positive pancreatic carcinomas, antigen-experienced T lymphocytes in fresh peripheral blood mononuclear cells were shown by IFN-gamma enzyme-linked immunospot using muRas peptides (5-21) that encompass both HLA class I (HLA-A2)- and class II-restricted (HLA-DRB1) epitopes. Six of 19 patients (32%) were found to have a specific T-cell response against individual mutation-specific ras(5-21) but not against other ras mutations or wild-type ras. In contrast, none of 19 healthy subjects had T cells specifically secreting IFN-gamma (P = 0.004). The T-cell response consisted of both CD8(+) and CD4(+) T cells but was dominated by CD8 T cells in three of four patients. MuRas(5-14) and muRas(6-14) were shown to specifically induce CD8(+) T-cell mediated cytotoxicity against HLA-A2-positive, muRas-bearing pancreatic carcinoma cells. The T-cell response was not correlated with prognostic or clinical variables such as tumor-node-metastasis status, stage, or survival. In conclusion, a natural T-cell response against muRas proteins that could be exploited for immunostimulatory therapeutic approaches has been shown in a significant proportion of patients with pancreatic cancer. 相似文献
999.
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. 总被引:5,自引:0,他引:5
David A Brown Carsten Stephan Robyn L Ward Mathew Law Mark Hunter Asne R Bauskin Janaki Amin Klaus Jung Eleftherios P Diamandis Garret M Hampton Pamela J Russell Graham G Giles Samuel N Breit 《Clinical cancer research》2006,12(1):89-96
PURPOSE: Current serum testing for the detection of prostate cancer (PCa) lacks specificity. On diagnosis, the optimal therapeutic pathway is not clear and tools for adequate risk assessment of localized PCa progression are not available. This leads to a significant number of men having unnecessary diagnostic biopsies and surgery. A search for novel tumor markers identified macrophage inhibitory cytokine 1 (MIC-1) as a potentially useful marker. Follow-up studies revealed MIC-1 overexpression in local and metastatic PCa whereas peritumoral interstitial staining for MIC-1 identified lower-grade tumors destined for recurrence. Consequently, we sought to assess serum MIC-1 measurement as a diagnostic tool. EXPERIMENTAL DESIGN: Using immunoassay determination of serum MIC-1 concentration in 1,000 men, 538 of whom had PCa, we defined the relationship of MIC-1 to disease variables. A diagnostic algorithm (MIC-PSA score) based on serum levels of MIC-1, total serum prostate-specific antigen, and percentage of free prostate-specific antigen was developed. RESULTS: Serum MIC-1 was found to be an independent predictor of the presence of PCa and tumors with a Gleason sum > or =7. We validated the MIC-PSA score in a separate population and showed an improved specificity for diagnostic blood testing for PCa over percentage of free prostate-specific antigen, potentially reducing unnecessary biopsies by 27%. CONCLUSIONS: Serum MIC-1 is an independent marker of the presence of PCa and tumors with a Gleason sum of > or =7. The use of serum MIC-1 significantly increases diagnostic specificity and may be a future tool in the management of PCa. 相似文献
1000.
Rupert Bartsch Sabine Fromm Margaretha Rudas Catharina Wenzel Stefanie Harbauer Karl Roessler Klaus Kitz Guenther G. Steger Hajo-Dirk Weitmann Richard Poetter Christoph C. Zielinski Karin Dieckmann 《Radiotherapy and oncology》2006,80(3):313-317
BACKGROUND: Brain metastases have evolved from a rare to a frequently encountered event in advanced breast cancer due to advances in palliative systemic treatment. PATIENTS AND METHODS: All Patients treated at our centre from 1994 to 2004 with WBRT for brain metastases from breast cancer were included. We performed a multivariate analysis (Cox regression) to explore which factors are able to influence significantly cerebral time to progression (TTP) and overall survival (metastatic sites [visceral versus non-visceral], Karnofsky performance score [KPS], age, intensified local treatment [boost irradiation, neuro-surgical resection] further systemic treatment). RESULTS: Overall 174 patients, median age 51 years, range 27-76 years, were included. Median TTP was 3 months (m), range 1-33+ m. Median overall survival was 7 m, range 1-44 m. Factors significantly influencing TTP were KPS (p = 0.002), intensified local treatment (p < 0.001), and palliative systemic treatment (p = 0.001). Factors significantly influencing survival were intensified local treatment (p = 0.004), metastatic sites (p = 0.008), KPS (p = 0.006), and palliative systemic treatment (p < 0.001). CONCLUSION: As shown by the significant influence of metastatic sites, some patients die from their advanced systemic tumour situation before they would die from cerebral progression. In other individuals however, intensified local treatment and systemic treatment appear to influence cerebral time to progression and overall survival. 相似文献